Clinical Trials for Bortezomib

5 Open Trials

Trial TypeProtocol No. &
Open Date
Summary
TreatmentVICCHEM1377
03/14/2014
A Phase 1 Study of Arry-520 and Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
TreatmentVICCHEM12107
03/31/2013
A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LD-DEX) versus Bortezomib and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (MM)
TreatmentCOGAAML1031
08/24/2011
AAML1031 - A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD
TreatmentECOGHEME2408
05/10/2011
A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Follwed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma
TreatmentVICCBMT1020
11/15/2010
Impact of First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment with Velcade Based Therapy

Back to Find By Drug

You do not have JavaScript enabled. This site works better with JavaScript turned on.